Once a week, subcutaneous injection of C5 supplement inhibitor ULTOMIRIS, treatment of burst sleep-based hemoglobinuria reached the clinical endpoint of Stage III

Alexion Pharmaceuticals announced that its weekly patient self-inderite injection ULTOMIRIS treatment of bisonal hemoglobinuria (PNH) has reached the primary end of the trialOn the 71st day, subcutaneous injection ulTOMIRIS reached the main goal of non-poor pharmacokinetics (PK) compared to intravenous ULTOMIRISDrJohn Orloff, Executive Vice President and Head of Research and Development at Alexion, said, ???These data suggest that subcutaneous injections of ULTOMIRIS can provide??? The same rapid, complete and continuous recombination inhibition effect as intravenous ULTOMIRIS, but also provides new treatment options for patients willing to take the drug on their own"
on ultomiris (ravulizumab-cwvz)ULTOMIRIS is the first and only long-acting C5 supplement inhibitor that acts by inhibiting C5 proteins in end-to-end complement cascade reactionsThe complement cascade reaction is part of the body'simmunesystem, and overactivation can damage the body's healthy cellsULTOMIRIS has been approved in the United States, the European Union and Japan for the treatment of adult patients with pontoonaryanoprotein (PNH)about the burst of nocturnal hemoglobinuria (PNH)bursts of hemoglobinuria is a serious and rare blood abnormality characterized by the destruction of red blood cells, also known as hemolytic bloodWhen the complement system overreacts, PNH occurs, causing the body to attack its own red blood cellsPNH is often difficult to diagnosis , with diagnostic times from one to five years or more PNH patients may experience a range of symptoms, such as fatigue, difficulty swallowing, shortness of breath, dull urination of abdominal pain, and anemia The most serious consequence of chronic hemolysis is the formation of blood clots, which can occur in blood vessel s throughout the body, damaging vital organs and leading to premature death